ArticleCancer cell international2015
Down-regulation of miR-133a and miR-539 are associated with unfavorable prognosis in patients suffering from osteosarcoma.
Article in Cancer cell international, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It has been retracted, and should not be counted. Cited by 18 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 1 synthesis or guideline pooled it, 28 citations in OpenAlex.
- Utility of miR‑133a‑3p as a diagnostic indicator for hepatocellular carcinoma: An investigation combined with GEO, TCGA, meta‑analysis and bioinformatics.Molecular medicine reports · 2018Pooled it
- Emerging roles of MiR-133a in human cancers.Journal of Cancer · 2021Article
- MicroRNA-539 inhibits the progression of Wilms' Tumor through downregulation of JAG1 and Notch1/3.Cancer biomarkers : section A of Disease markers · 2019Article
- miR-539-3P inhibits proliferation and invasion of gastric cancer cells by targeting CTBP1.International journal of clinical and experimental pathology · 2019Article
- Astragalus polysaccharides decrease proliferation, migration, and invasion but increase apoptosis of human osteosarcoma cells by up-regulation of microRNA-133a.Brazilian journal of medical and biological research = Revista brasileira de pesquisas medicas e biologica · 2018Article
- MicroRNA-539 inhibits colorectal cancer progression by directly targeting SOX4.Oncology letters · 2018Article
- Surgical outcome and clinicopathological characteristics of emergency presentation elective cases of colorectal cancer.Archives of medical science : AMS · 2018Article
- Down-regulation of MiR-539 Indicates Poor Prognosis in Patients with Pancreatic Cancer.Open life sciences · 2018Article
- MiR-539 inhibits proliferation and migration of triple-negative breast cancer cells by down-regulating LAMA4 expression.Cancer cell international · 2018Article
- Investigation of clinicopathological parameters in emergency colorectal cancer surgery: a study of 67 patients.Archives of medical science : AMS · 2017Article
- Identification of the miRNA-mRNA regulatory network of small cell osteosarcoma based on RNA-seq.Oncotarget · 2017Article
- miR-539 inhibits FSCN1 expression and suppresses hepatocellular carcinoma migration and invasion.Oncology reports · 2017Article
- Article
- Extensive miRNA expression analysis in craniopharyngiomas.Child's nervous system : ChNS : official journal of the International Society for Pediatric Neurosurgery · 2016Article
- miR-422a is an independent prognostic factor and functions as a potential tumor suppressor in colorectal cancer.World journal of gastroenterology · 2016Article
- The plasma miR-125a, miR-361 and miR-133a are promising novel biomarkers for Late-Onset Hypogonadism.Scientific reports · 2016Article
- Prognostic value of decreased microRNA-133a in solid cancers: a meta-analysis.OncoTargets and therapy · 2016Article
- Retraction Note: Down-regulation of miR-133a and miR-539 are associated with unfavorable prognosis in patients suffering from osteosarcoma.Cancer cell international · 2016Article
Corrections and comments
- Retraction · 2016-11-04Concerns/Issues about Authorship/Affiliation · Compromised Peer Review · Investigation by Journal/Publisher · Plagiarism of/in Article ·
- Retracted
Authors and funding
7 authors at 6 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundMicroRNAs (miRNAs) play key roles in cancer development and progression. The purpose of the present study was to determine the expression levels of miR-133a and miR-539 in osteosarcoma patients and to further investigate the clinicopathological, and prognostic value of these miRNAs.
methodsThe expression levels of miR-133a and miR-539 were determined by qRT-PCR. Associations between miRNAs expressions and various clinicopathological characteristics were analyzed. Survival rate was determined with Kaplan-Meier and statistically analyzed with the log-rank method between groups. Survival data were evaluated through multivariate Cox regression analysis.
resultsOur findings revealed that the miR-133a expression was significantly decreased in clinical osteosarcoma tissues compared to adjacent normal bone tissues. The expression level of miR-539 was decreased in clinical osteosarcoma tissues as compared to those adjacent normal tissues. Low expressions of miR-133a and miR-539 were significantly association with advanced TNM stage (P = 0.002; P = 0.001), and metastasis or recurrence (P = 0.001; P = 0.01). Furthermore, Kaplan-Meier survival analysis and log-rank test showed that the low expressions of miR-133a and miR-539 were correlated with the reduced overall survival of osteosarcoma patients. Multivariate Cox proportional hazards model showed that decreased expressions of miR-133a and miR-539 (P = 0.007; P = 0.02), TNM stage (P = 0.001; P = 0.002), and metastasis or recurrence (P = 0.005; P = 0.026) were independent prognostic markers of overall survival of patients.
conclusionThese results suggest that decreased miR-133a and miR-539 expressions may participate in the progression of osteosarcoma. Together, these results showed that miR-133a and miR-539 may have their role in both progression and prognosis of osteosarcoma.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.